KEVIN WARE: Open Payments
NPI 1609817980 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$282,949 in 388 payments from 10 companies in 2025. Trend: 2023 $200,494 · 2024 $249,672 · 2025 $282,949
Speaker / faculty: $219,730Travel & lodging: $41,637Consulting: $14,220Food & beverage: $7,362
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 216 | $160,499 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 145 | $114,257 |
| Vanda Pharmaceuticals Inc. | 15 | $7,728 |
| E.R. Squibb & Sons, L.L.C. | 5 | $228 |
| Janssen Pharmaceuticals, Inc | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $22 |
| Gilead Sciences, Inc. | 1 | $20 |
| Braeburn Inc. | 1 | $16 |
Products named: LYBALVI, CAPLYTA, ARISTADA, FANAPT, COBENFY, INVEGA SUSTENNA, Auvelity, Quviviq.
Industry payments across OH — which companies pay providers there.
